SGLT2 inhibition with Enavogliflozin significantly improves cognitive function and reduces Aβ pathology in the 5XFAD mouse model of Alzheimer's disease. This evidence concerns the gene SLC5A2 and early-onset autosomal dominant Alzheimer disease.